Abstract 5737
Background
HER2 breast cancer status determines patients’ eligibility for targeted therapy. HER2 level of amplification is associated with a better response to anti-HER2 therapy. Benefit of anti-HER2 therapy for equivocal cases remains debated.
Methods
We aimed to better characterize HER2-equivocal breast cancers by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) according to 2018 ASCO/CAP guidelines using PAM50 gene expression-based molecular subtyping and to investigate genome-wide copy number alterations of these cases. PAM50 (nCounter assay; Nanostring) was performed on RNA from FFPE samples of 60 HER2-equivocal cases. These cases were subsequently analyzed by Agilent 60-mer oligonucleotide microarrays for array-based comparative genomic hybridization (aCGH).
Results
The 60 HER2-equivocal cases were classified as Luminal B in 31 cases (52%), HER2-Enriched in 14 cases (23%), Luminal A in 13 cases (22%) and Basal-like in 2 cases (3%) using PAM50. By IHC, 52 cases (87%) were ER+, 43 (72%) were also PgR+, 40 (67%) were grade III and 45 (75%) showed a high Ki67 > 20%. With aCGH, 23 cases (38%) presented chr 17q large copy number gain, 14 (23%) showed segmental copy number gain including HER2, 10 (17%) showed HER2 amplification, one (2%) showed a large copy number loss and 12 cases (20%) didn’t show any copy number alteration of the chr 17. Out of the 14 PAM50 HER2-Enriched cases, only 5 showed HER2 genomic amplification (Table). In total, 14 cases (23%) were discordant between molecular classification and genomic alteration status of the chr 17.Table:
260P
Genomic alterations of chromosome 17 | Basal- like | HER2- Enriched | Luminal A | Luminal B | Total |
---|---|---|---|---|---|
HER2 amplified | 0 | 5 | 2 | 3 | 10 |
Large copy number gain | 0 | 1 | 5 | 17 | 23 |
Segmental copy number gain | 2 | 5 | 4 | 3 | 14 |
No alteration | 0 | 3 | 2 | 7 | 12 |
Large copy number loss | 0 | 0 | 0 | 1 | 1 |
Total | 2 | 14 | 13 | 31 | 60 |
Conclusions
Using PAM50, the majority of HER2-equivocal cases were classified as Luminal tumors (Luminal B 52% and A 22%) and harbored mostly at the genomic level chr 17 segmental or large copy number gains. As there is no evidence of benefit of anti-HER2 therapy in these cases, it emphasizes the need of genomic status determination of HER2-equivocal cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Anne Vincent-Salomon.
Funding
Has not received any funding.
Disclosure
P. Morel: Full / Part-time employment: Nanostring. H.A. Brauer: Full / Part-time employment: Nanosting. A. Vincent-Salomon: Advisory / Consultancy, Consulting fees: Roche; Advisory / Consultancy, Consulting fees: AstraZeneca; Non-remunerated activity/ies, Contracted Research: Nanostring. All other authors have declared no conflicts of interest.
Resources from the same session
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract